Denisa Janíčková Žďárská
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Denisa Janíčková Žďárská has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Jan Brož
Interní klinika
4 shared publications - Marek Brabec
Institute of Computer Science of the Czech Academy of Sciences, Prague 8, Czech Republic
4 shared publications - Jana Urbanová
Third Faculty of Medicine of Faculty Hospital Královské Vinohrady, Charles University, Prague, Czech Republic
3 shared publications - Anna Holubová
First Faculty of Medicine, Charles University, Prague, Czech Republic
2 shared publications - Dominik Fiala
First Faculty of Medicine, Charles University, Prague, Czech Republic
2 shared publications - Eirik Årsand
Department of Computer Science, UiT the Arctic University of Norway, Tromsø, Norway
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (6) , 1085-1092
SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes
Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and contributes significantly to morbidity and mortality in developed countries. Current clinical practice primarily relies on dietary and lifestyle modifications, while specialized obesity management is used less frequently. However, the long-term efficacy of these approaches remains unsatisfactory. Among pharmacological options, gliflozins have emerged as a promising class of agents with potential benefits in reducing histological activity and improving the prognosis of MASLD/MASH. The beneficial effects of gliflozins in diabetes, cardiology, and nephrology have already been demonstrated, and their use is becoming increasingly common across various clinical indications. However, their role in the treatment of MASLD/MASH has not yet been fully clarified. Preliminary studies suggest that gliflozins may positively influence disease progression in these conditions. This article provides a comprehensive overview of MASLD/MASH and reviews current evidence regarding the therapeutic effects of gliflozins on these liver diseases.
- 29 June 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (6) , 1085-1092
Open AccessSGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD): Mechanisms, clinical benefits, and outcomes
Metabolic dysfunction-associated steatohepatitis (MASH) represents a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) and contributes significantly to morbidity and mortality in developed countries. Current clinical practice primarily relies on dietary and lifestyle modifications, while specialized obesity management is used less frequently. However, the long-term efficacy of these approaches remains unsatisfactory. Among pharmacological options, gliflozins have emerged as a promising class of agents with potential benefits in reducing histological activity and improving the prognosis of MASLD/MASH. The beneficial effects of gliflozins in diabetes, cardiology, and nephrology have already been demonstrated, and their use is becoming increasingly common across various clinical indications. However, their role in the treatment of MASLD/MASH has not yet been fully clarified. Preliminary studies suggest that gliflozins may positively influence disease progression in these conditions. This article provides a comprehensive overview of MASLD/MASH and reviews current evidence regarding the therapeutic effects of gliflozins on these liver diseases.
- Open Access
- 28 April 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e35064
A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study
Background: Today’s diabetes-oriented telemedicine systems can gather and analyze many parameters like blood glucose levels, carbohydrate intake, insulin doses, and physical activity levels (steps). Information collected can be presented to patients in a variety of graphical outputs. Despite the availability of several technical means, a large percentage of patients do not reach the goals established in their diabetes treatment. Objective: The objective of the study was to evaluate the benefits of the Diani telemedicine system for the treatment of patients with type 1 diabetes mellitus. Methods: Data were collected during a 24-week feasibility study. Patients responded to the World Health Organization Quality of Life – BREF (WHOQOL-BREF) questionnaire and a system evaluation questionnaire. The level of glycated hemoglobin (HbA1c) and the patient’s body weight were measured, and the patient’s use of the telemedicine system and their daily physical activity level were monitored. All data were sent from the patient’s device to the Diani server using a real-time diabetes diary app. Wilcoxon and Friedman tests and the linear mixed effects method were used for data analysis. Results: This study involved 10 patients (men: n=5; women: n=5), with a mean age of 47.7 (SD 19.3) years, a mean duration of diabetes of 10.5 (SD 8.6) years, and a mean HbA1c value of 59.5 (SD 6.7) mmol/mol. The median number of days the patients used the system was 84. After the intervention, the mean HbA1c decreased by 4.35 mmol/mol (P=.01). The patients spent 18.6 (SD 6.8) minutes on average using the app daily. After the intervention, the number of patients who measured their blood glucose level at least 3 times a day increased by 30%. The graphical visualization of the monitored parameters, automatic transmission of measured data from the glucometer, compatibility, and interconnection of individual devices when entering data were positively evaluated by patients. Conclusions: The Diani system was found to be beneficial for patients with type 1 diabetes mellitus in terms of managing their disease. Patients perceived it positively; it strengthened their knowledge of diabetes and their understanding of the influences of the measured values on the management of their disease. Its use had a positive effect on the HbA1c level.
- 28 April 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e35064
Open AccessA Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study
Background: Today’s diabetes-oriented telemedicine systems can gather and analyze many parameters like blood glucose levels, carbohydrate intake, insulin doses, and physical activity levels (steps). Information collected can be presented to patients in a variety of graphical outputs. Despite the availability of several technical means, a large percentage of patients do not reach the goals established in their diabetes treatment. Objective: The objective of the study was to evaluate the benefits of the Diani telemedicine system for the treatment of patients with type 1 diabetes mellitus. Methods: Data were collected during a 24-week feasibility study. Patients responded to the World Health Organization Quality of Life – BREF (WHOQOL-BREF) questionnaire and a system evaluation questionnaire. The level of glycated hemoglobin (HbA1c) and the patient’s body weight were measured, and the patient’s use of the telemedicine system and their daily physical activity level were monitored. All data were sent from the patient’s device to the Diani server using a real-time diabetes diary app. Wilcoxon and Friedman tests and the linear mixed effects method were used for data analysis. Results: This study involved 10 patients (men: n=5; women: n=5), with a mean age of 47.7 (SD 19.3) years, a mean duration of diabetes of 10.5 (SD 8.6) years, and a mean HbA1c value of 59.5 (SD 6.7) mmol/mol. The median number of days the patients used the system was 84. After the intervention, the mean HbA1c decreased by 4.35 mmol/mol (P=.01). The patients spent 18.6 (SD 6.8) minutes on average using the app daily. After the intervention, the number of patients who measured their blood glucose level at least 3 times a day increased by 30%. The graphical visualization of the monitored parameters, automatic transmission of measured data from the glucometer, compatibility, and interconnection of individual devices when entering data were positively evaluated by patients. Conclusions: The Diani system was found to be beneficial for patients with type 1 diabetes mellitus in terms of managing their disease. Patients perceived it positively; it strengthened their knowledge of diabetes and their understanding of the influences of the measured values on the management of their disease. Its use had a positive effect on the HbA1c level.
- Open Access
- 19 November 2021
- Published by JMIR Publications Inc. in JMIR Preprints
A Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study (Preprint)
BACKGROUND Today’s diabetes-oriented telemedicine systems can gather and analyze many parameters like blood glucose levels, carbohydrate intake, insulin doses, and physical activity levels (steps). Information collected can be presented to patients in a variety of graphical outputs. Despite the availability of several technical means, a large percentage of patients do not reach the goals established in their diabetes treatment. OBJECTIVE The objective of the study was to evaluate the benefits of the Diani telemedicine system for the treatment of patients with type 1 diabetes mellitus. METHODS Data were collected during a 24-week feasibility study. Patients responded to the World Health Organization Quality of Life – BREF (WHOQOL-BREF) questionnaire and a system evaluation questionnaire. The level of glycated hemoglobin (HbA1c) and the patient’s body weight were measured, and the patient’s use of the telemedicine system and their daily physical activity level were monitored. All data were sent from the patient’s device to the Diani server using a real-time diabetes diary app. Wilcoxon and Friedman tests and the linear mixed effects method were used for data analysis. RESULTS This study involved 10 patients (men: n=5; women: n=5), with a mean age of 47.7 (SD 19.3) years, a mean duration of diabetes of 10.5 (SD 8.6) years, and a mean HbA1c value of 59.5 (SD 6.7) mmol/mol. The median number of days the patients used the system was 84. After the intervention, the mean HbA1c decreased by 4.35 mmol/mol (P=.01). The patients spent 18.6 (SD 6.8) minutes on average using the app daily. After the intervention, the number of patients who measured their blood glucose level at least 3 times a day increased by 30%. The graphical visualization of the monitored parameters, automatic transmission of measured data from the glucometer, compatibility, and interconnection of individual devices when entering data were positively evaluated by patients. CONCLUSIONS The Diani system was found to be beneficial for patients with type 1 diabetes mellitus in terms of managing their disease. Patients perceived it positively; it strengthened their knowledge of diabetes and their understanding of the influences of the measured values on the management of their disease. Its use had a positive effect on the HbA1c level.
- 19 November 2021
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Telemedicine System Intervention for Patients With Type 1 Diabetes: Pilot Feasibility Crossover Intervention Study (Preprint)
BACKGROUND Today’s diabetes-oriented telemedicine systems can gather and analyze many parameters like blood glucose levels, carbohydrate intake, insulin doses, and physical activity levels (steps). Information collected can be presented to patients in a variety of graphical outputs. Despite the availability of several technical means, a large percentage of patients do not reach the goals established in their diabetes treatment. OBJECTIVE The objective of the study was to evaluate the benefits of the Diani telemedicine system for the treatment of patients with type 1 diabetes mellitus. METHODS Data were collected during a 24-week feasibility study. Patients responded to the World Health Organization Quality of Life – BREF (WHOQOL-BREF) questionnaire and a system evaluation questionnaire. The level of glycated hemoglobin (HbA1c) and the patient’s body weight were measured, and the patient’s use of the telemedicine system and their daily physical activity level were monitored. All data were sent from the patient’s device to the Diani server using a real-time diabetes diary app. Wilcoxon and Friedman tests and the linear mixed effects method were used for data analysis. RESULTS This study involved 10 patients (men: n=5; women: n=5), with a mean age of 47.7 (SD 19.3) years, a mean duration of diabetes of 10.5 (SD 8.6) years, and a mean HbA1c value of 59.5 (SD 6.7) mmol/mol. The median number of days the patients used the system was 84. After the intervention, the mean HbA1c decreased by 4.35 mmol/mol (P=.01). The patients spent 18.6 (SD 6.8) minutes on average using the app daily. After the intervention, the number of patients who measured their blood glucose level at least 3 times a day increased by 30%. The graphical visualization of the monitored parameters, automatic transmission of measured data from the glucometer, compatibility, and interconnection of individual devices when entering data were positively evaluated by patients. CONCLUSIONS The Diani system was found to be beneficial for patients with type 1 diabetes mellitus in terms of managing their disease. Patients perceived it positively; it strengthened their knowledge of diabetes and their understanding of the influences of the measured values on the management of their disease. Its use had a positive effect on the HbA1c level.
- Open Access
- 1 June 2016
- Published by Taylor & Francis in Open Access Journal of Clinical Trials
- Vol. 8, 13-20
An international, multicenter, observational survey to evaluate diabetes control in subjects using insulin for the treatment of type 1 and type 2 diabetes mellitus in the Czech Republic and Slovak Republic: study protocol for a cross-sectional survey
Background: Despite the improvements in insulin therapy, a large number of patients fail to achieve their target glycated hemoglobin (HbA1c) levels. Control of diabetes is often unsatisfactory because the patient does not know about the principles of successful insulin therapy (ie, blood glucose self-monitoring, the principles of insulin administration, titration, current dose adjustments, dietary recommendations, and physical activity preventive measures) or because these principles are applied incorrectly or insufficiently. Furthermore, the fear of hypoglycemia may lead to maintaining higher than recommended blood glucose levels. Methods/design: This is a noninterventional, international study focusing on a questionnaire survey of diabetes patients (patient-reported outcome) treated with insulin for at least 1 year. It is designed so that the data obtained reflect real access of patients to insulin treatment. The primary objective is to show the results of glycemic control of diabetes (HbA1c) achieved in diabetes patients treated with at least one dose of insulin. The secondary objective is to monitor the factors potentially affecting these results, which include the frequency and other characteristics of hypoglycemia, the frequency of blood glucose self-monitoring, and the effects produced when the results are employed in adjusting the therapy. Furthermore, the study investigates factors related to the principles of insulin administration, dietary regime, and exercise habits. The study will enroll a total of 1,500 patients with type 1 and type 2 diabetes in 150 centers: two-thirds in the Czech Republic and one-third in the Slovak Republic. Discussion: The study is primarily aimed at determining the percentage of insulin-treated diabetes patients reaching the recommended targets for glycemic control (HbA1c). Furthermore, it attempts to identify and describe in detail the factors of failure in achieving the therapeutic goals. An analysis of the data thus obtained may result in recommendations on how to reduce and eliminate all the identified negative factors in the future.
- 1 June 2016
- Published by Taylor & Francis in Open Access Journal of Clinical Trials
- Vol. 8, 13-20
Open AccessAn international, multicenter, observational survey to evaluate diabetes control in subjects using insulin for the treatment of type 1 and type 2 diabetes mellitus in the Czech Republic and Slovak Republic: study protocol for a cross-sectional survey
Background: Despite the improvements in insulin therapy, a large number of patients fail to achieve their target glycated hemoglobin (HbA1c) levels. Control of diabetes is often unsatisfactory because the patient does not know about the principles of successful insulin therapy (ie, blood glucose self-monitoring, the principles of insulin administration, titration, current dose adjustments, dietary recommendations, and physical activity preventive measures) or because these principles are applied incorrectly or insufficiently. Furthermore, the fear of hypoglycemia may lead to maintaining higher than recommended blood glucose levels. Methods/design: This is a noninterventional, international study focusing on a questionnaire survey of diabetes patients (patient-reported outcome) treated with insulin for at least 1 year. It is designed so that the data obtained reflect real access of patients to insulin treatment. The primary objective is to show the results of glycemic control of diabetes (HbA1c) achieved in diabetes patients treated with at least one dose of insulin. The secondary objective is to monitor the factors potentially affecting these results, which include the frequency and other characteristics of hypoglycemia, the frequency of blood glucose self-monitoring, and the effects produced when the results are employed in adjusting the therapy. Furthermore, the study investigates factors related to the principles of insulin administration, dietary regime, and exercise habits. The study will enroll a total of 1,500 patients with type 1 and type 2 diabetes in 150 centers: two-thirds in the Czech Republic and one-third in the Slovak Republic. Discussion: The study is primarily aimed at determining the percentage of insulin-treated diabetes patients reaching the recommended targets for glycemic control (HbA1c). Furthermore, it attempts to identify and describe in detail the factors of failure in achieving the therapeutic goals. An analysis of the data thus obtained may result in recommendations on how to reduce and eliminate all the identified negative factors in the future.
- Open Access
- 1 November 2013
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 7 (6) , 1644-1645
Could Continuous Glucose Monitoring Facilitate Identifying Diabetes Patients with a Higher Risk of Hypoglycemia during Driving?
- 1 November 2013
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 7 (6) , 1644-1645
Open AccessCould Continuous Glucose Monitoring Facilitate Identifying Diabetes Patients with a Higher Risk of Hypoglycemia during Driving?